0001193125-16-802977.txt : 20170130 0001193125-16-802977.hdr.sgml : 20170130 20161223120202 ACCESSION NUMBER: 0001193125-16-802977 CONFORMED SUBMISSION TYPE: CORRESP PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20161223 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Spring Bank Pharmaceuticals, Inc. CENTRAL INDEX KEY: 0001566373 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 522386345 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: CORRESP BUSINESS ADDRESS: STREET 1: 86 SOUTH STREET CITY: HOPKINTON STATE: MA ZIP: 01748 BUSINESS PHONE: 508-473-5993 X119 MAIL ADDRESS: STREET 1: 86 SOUTH STREET CITY: HOPKINTON STATE: MA ZIP: 01748 CORRESP 1 filename1.htm CORRESP

SPRING BANK PHARMACEUTICALS, INC.

86 South Street

Hopkinton, MA 01748

December 23, 2016

VIA EDGAR

Securities and Exchange Commission

Division of Corporation Finance

100 F Street, N.E.

Washington, D.C. 20549

 

Re: Spring Bank Pharmaceuticals, Inc.

Registration Statement on Form S-1

File No. 333-215122

Request for Acceleration                    

Ladies and Gentlemen:

Pursuant to Rule 461 promulgated under the Securities Act of 1933, as amended, Spring Bank Pharmaceuticals, Inc. (the “Registrant”) hereby requests acceleration of the effective date of its Registration Statement on Form S-1 (File No. 333-215122), as amended (the “Registration Statement”), so that it may become effective at 4:00 p.m. Eastern time on December 29, 2016, or as soon thereafter as practicable.

The Registrant hereby acknowledges that:

 

  (a) should the Securities and Exchange Commission (the “Commission”) or the staff, acting pursuant to delegated authority, declare the Registration Statement effective, it does not foreclose the Commission from taking any action with respect to the Registration Statement;

 

  (b) the action of the Commission or the staff, acting pursuant to delegated authority, in declaring the Registration Statement effective, does not relieve the Registrant from its full responsibility for the adequacy and accuracy of the disclosure in the Registration Statement; and

 

  (c) the Registrant may not assert staff comments and the declaration of effectiveness of the Registration Statement as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States.

[The remainder of this page is intentionally left blank.]

Very truly yours,
SPRING BANK PHARMACEUTICALS, INC.
By:  

/s/ Martin Driscoll

Name:   Martin Driscoll
Title:   President and Chief Executive Officer

[Signature Page to Request for Acceleration]